Skip to content

Molecular Imaging of Breast Cancer With Breast PET/CT

Molecular Imaging of Breast Cancer With Breast PET/CT

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00584753
Enrollment
4
Registered
2008-01-02
Start date
2007-04-30
Completion date
2011-07-31
Last updated
2013-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer

Brief summary

This study is a feasibility study to determine if a combined breast PET/CT scanner can image malignant functional activity while determining anatomical structure in the same clinical setting for patients with breast cancer. End-points of this study are whether women will accept the imaging position and timing, and whether functional properties of breast cancer can be imaged with this device. The secondary purpose of this study is to explore protocol parameters with a view to optimizing imaging performance whilst minimizing patient discomfort. Imaging results will be compared to histological samples to determine ground truth.

Detailed description

PET is literally a molecular imaging modality. In monitoring the patient's response to a specific chemotherapeutic regime, baseline and subsequent PET/CT scans can be used to quantitatively determine the therapeutic effect of the regime, using the standard uptake value (SUV), a common metric in PET imaging. The breast PET/CT system will facilitate molecular imaging of breast cancer using a number of radiolabeled molecules, available both commercially (18-FDG) and from the research environment.

Interventions

Positron emission tomography and computed tomography

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Normal Adult Volunteers * Female, at least 18 years of age * Ability to lie motionless for up to 20 minutes Patient Volunteers * Female, at least 18 years of age * Diagnostic findings from prior mammography highly suggestive of invasive breast carcinoma (BI-RADS category 5) * Not pregnant or breast-feeding * Ability to lie motionless for up to 20 minutes

Exclusion criteria

* Normal Adult Volunteers * Inability to understand the risks and benefits of the study Patient Volunteers * Recent breast biopsy * Diagnostic findings from prior mammography highly suggestive of noninvasive ductal or lobular carcinoma * Uncontrolled diabetes * Diabetic and blood sugar level \> 200 mg/dL * Positive urine pregnancy test or currently breast-feeding * Inability to understand the risks and benefits of the study

Design outcomes

Primary

MeasureTime frame
End-points of this study are whether women will accept the imaging position and timing, and whether functional properties of breast cancer can be imaged with this device.5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026